ASBPW — Aspire Biopharma Holdings, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1847345 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 28,353 | 5,750 | -1,646,169 | -3,222,892 | 7,117,147 | 5,857,024 | 3,248,684 |
| Dec 2025 | 4,261 | -1,000 | -1,849,424 | -4,707,734 | 1,312,166 | 1,003,904 | 7,688,495 |
| Sep 2025 | 1,941 | 884 | -1,145,497 | -1,850,493 | 2,403,129 | 1,948,271 | 13,870,407 |
| Jun 2025 | 0 | — | -799,890 | -1,981,293 | 989,422 | 206,233 | 10,606,207 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-4,923,488
Investing CF
$38,258
Financing CF
$5,923,759
CapEx
$-18,822
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-27,258,081
Inventory
$253,160
Receivables
$0
ST Investments
—
EBIT TTM
$-15,949,573
Pretax Income TTM
$-24,480,848
Interest Exp TTM
$8,531,275
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$34,555
EBITDA
—
Free Cash Flow
$21,925,390
Enterprise Value
—
Total Cash
$5,857,024
Total Debt
$1,499,214
Shares Out
—
Trailing EPS
—
Book Value
$23.10
ROE
—
ROA
119.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 6,202 | -19,351,291 | -24,480,848 | 1,312,166 | 7,688,495 | — | -4,923,488 |
| Dec 2024 | 0 | -1,210,871 | -1,309,872 | 147,989 | 1,688,077 | — | -265,186 |
| Dec 2023 | 0 | -1,340,168 | 4,464,079 | 46,174 | 534,035 | — | 11,136 |
| Dec 2022 | 0 | -596,491 | -597,117 | 22,538 | 151,328 | — | -142,905 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $949.47B | $1064.74 | — |
| JNJ | JOHNSON & JOHNSON | $554.09B | $230.18 | — |
| ABBV | AbbVie Inc. | $376.54B | $213.12 | — |
| MRK | Merck & Co., Inc. | $295.69B | $119.72 | — |
| AZN | ASTRAZENECA PLC | $290.30B | $187.19 | — |
News headlines (Yahoo Finance, 1h cache)
Aspire Biopharma (ASBP) Authorizes $5M Share Repurchase Program
2026-05-13 17:46 · Yahoo
Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio
2026-05-07 15:00 · Yahoo
Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition
2026-04-20 12:30 · Yahoo
Aspire Biopharma's Buzz Bomb(TM) Caffeine Company's Brand Ambassador, Ashley Paulson, to Attempt Fastest 100-Mile Treadmill Run at 2026 Boston Marathon Expo
2026-04-17 12:00 · Yahoo
Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 Revenue
2026-04-16 12:30 · Yahoo
Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion
2026-04-15 12:00 · Yahoo
Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion
2026-03-19 12:00 · Yahoo
Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director
2026-03-17 12:30 · Yahoo
Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements
2026-02-20 13:00 · Yahoo
Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record
2026-02-19 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.